(10S)-6,10,11-trihydroxy-8-(2-hydroxyacetyl)-1-methoxy-7,8,9,10-tetrahydrotetracene-5,12-dione

• 分子结构分类: 有机化合物 - 苯类化合物 - 并四苯
• 英文名称: (10S)-6,10,11-trihydroxy-8-(2-hydroxyacetyl)-1-methoxy-7,8,9,10-tetrahydrotetracene-5,12-dione
• 化学式: C₂₁H₁₈O₈
• 分子量: 398.4
• InChiKey: ASMBMDAJJWDKCJ-LYNSQETBSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.8
• 重原子数：
  29
• 可旋转键数：
  3
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.29
• 拓扑面积：
  141
• 氢给体数：
  4
• 氢受体数：
  8

文献信息

• [EN] ANTICANCER DRUG CONJUGATES<br/>[FR] CONJUGUÉS DE MÉDICAMENTS ANTICANCÉREUX
  申请人：ARIEL SCIENT INNOVATIONS LTD

  公开号：WO2017216791A9

  公开（公告）日：2018-02-08
• ANTI-WALL TEICHOIC ANTIBODIES AND CONJUGATES
  申请人：Genentech, Inc.

  公开号：EP3004161B1

  公开（公告）日：2019-10-02
• CONJUGATED KNOTTIN MINI-PROTEINS CONTAINING NON-NATURAL AMINO ACIDS
  申请人：THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY

  公开号：US20150266936A1

  公开（公告）日：2015-09-24

  Disclosed are knottin peptides containing non-natural amino acids so that they can be formed by chemical conjugation into two or more knottin monomers. The knottin monomers comprise a non-natural amino acid such as an aminooxy residue within the polypeptide sequence. The exemplified dimers were produced by oxime formation between two aldehyde groups present on a polyether linker and an aminooxy functional group that was site-specifically incorporated the knottin. Knottins variants based on EETI ( Ecballium elaterium trypsin inhibitor) and AgRP (Agouti-related protein) were engineered to contain integrin-binding loops. These dimers were shown to have increased binding strength to integrins on U87MG tumor cells, achieving significant increases in inhibition of cell adhesion and proliferation. Also disclosed are knottin monomers comprising an aminooxy residue; these may be conjugated to molecules such as doxorubicin.
• BIOORTHOGONAL COMPOUNDS COMPRISING A PROPARGYL GROUP FOR TREATING CANCER
  申请人：THE UNIVERSITY COURT OF THE UNIVERSITY OF EDINBURGH

  公开号：US20200289554A1

  公开（公告）日：2020-09-17

  A method of preparing an active agent or a salt thereof from a pro-drug first compound (1) comprising a propargyl group connected to an oxygen that is directly or indirectly connected to the active agent is provided, wherein the bond between the propargyl group and the oxygen is cleaved by reacting the first compound with palladium or gold, thereby releasing the active agent. Prodrug compositions suitable for use in the method are also provided.
• US9587001B2
  申请人：——

  公开号：US9587001B2

  公开（公告）日：2017-03-07